Why Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 7.82%
As of Monday, September 14, Nautilus Biotechnology, Inc.’s NAUT share price has dipped by 7.82%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Stock Evaluator: Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. NAUT
$0.95
0.04
4.41%
September 15, 2026 11:15:48 AM
EST
Volume: 230,609
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Commentary & Analysis
Why Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 7.94%
As of Thursday, September 10, Nautilus Biotechnology, Inc.’s NAUT share price has dipped by 7.94%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 10.27%
As of Thursday, September 10, Nautilus Biotechnology, Inc.’s NAUT share price has dipped by 10.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Up 5.25%
As of Wednesday, September 09, Nautilus Biotechnology, Inc.’s NAUT share price has surged by 5.25%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Up 11.12%
As of Wednesday, September 09, Nautilus Biotechnology, Inc.’s NAUT share price has surged by 11.12%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | NAUT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $115.3 | $3,715.1 | 23% |
|
| Shares Out (Mil) | 127.1 | 101.8 | 67% |
|
| Institutional Ownership | 46.6% | 89.5% | 20% |
|
| Float (Mil) | 67.5 | 71.1 | 53% |
|
| Beta | 0.81 | 1.19 | 48% |
|
| Avg Daily Volume (000s) | 1,255 | 792 | 75% |
|
| Price Change (52-week) |
28.3% | 84.0% | 72% |
|
| Growth | NAUT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 7.8% | na |
|
| Net Income (5yr) | (30.5%) | (11.2%) | 13% |
|
| EPS (5yr) | 2.8% | 2.5% | 35 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.9%) | (15.0%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NAUT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $800 | 0% |
|
| Net Income (TTM) (Mil) | ($57) | ($31) | 15% |
|
| EPS (TTM) | ($0.446) | ($0.300) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($50) | $47 | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($21) | $5 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $24 | $236 | 34% |
|
| Enterprise Value (Q1) (Mil) | $76 | $3,440 | 19% |
|
| Valuation | NAUT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.88 | 3.37 | 18% |
|
| P/E | na | 38.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.7 | na |
|
| Ratios | NAUT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 92.1% | 47.7% | 94% |
|
| Net Margin | na | (3.2%) | na |
|
| ROA | (30.0%) | (4.3%) | 17% |
|
| ROE | (36.2%) | (7.7%) | 18% |
|
| Liabilities to Assets | 19.8% | 41.1% | 13% |
|
| F-Score | 1 | 5 | 1% |
|
Nautilus Biotechnology, Inc. did not pass any screens on 9/14/2026.
